Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

p="name">Stephen Brannan, M.D., Central Nervous System Development Therapeutic Area Head, Takeda. "TOMMORROW is a significant study and represents a novel clinical milestone and trial for the Alzheimer's community as it evaluates pre-symptomatic patients."

About the TOMMORROW Trial
The TOMMORROW trial is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. The trial will use a genetic–based biomarker risk assignment algorithm comprised of APOE and TOMM40 genotypes and age, which is being studied to determine the risk of individuals developing MCI due to AD within a five year period. Cognitively normal individuals assessed as low risk will be assigned to receive placebo. Cognitively normal individuals assessed as high risk will be assigned to AD-4833 or placebo. The study duration is approximately five years or the time needed to achieve 410 conversions to MCI due to AD in the high risk group. Approximately 5,800 cognitively normal individuals aged 65-83 at 50 centers worldwide will be randomized into the study. The study will recruit internationally from large, diverse, community-based populations.

The study has two objectives:

For the genetic-based biomarker risk assignment algorithm, the primary objective is to qualify the risk assignment algorithm for identification of subjects at high risk of developing MCI due to AD within the next five years. The primary endpoint for the risk assignment algorithm is time to diagnosis of MCI due to AD for placebo-treated, high-risk subjects versus placebo-treated, low-risk subjects.

For AD-4833, considered an investigational drug for this use, the primary objective is to evaluate the efficacy of AD-4833 versus placebo in delaying the onset of MCI due to AD in cognitively normal individuals assessed as high risk based on the risk assignment algorithm. The primary endpoint is time to diagnosis of MCI due to AD for AD-4833-treated subjects versus pl
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the "Global and Chinese Medical X-ray Film Industry ... http://photos.prnewswire.com/prnh/20130307/600769 Global And ... professional and in-depth study on the current state of ... on the Chinese situation. The report provides a ...
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... /PRNewswire/ -- A new study suggests,strong variation in ... U.S. Anaphylaxis is a severe allergic,reaction that can ... differences in EpiPen prescribing, a marker of,anaphylaxis risk, ... low levels of vitamin D,from lack of sunshine, ...
... ,Celiac disease (CD) is an autoimmune inflammatory disease ... genetically susceptible persons by the ingestion of the ... The condition is thought to result from the ... response, leading to mucosal inflammation, villous atrophy, and ...
Cached Medicine Technology:Large Geographic Differences in EpiPen Prescriptions in the U.S.,From the Journal of Allergy and Clinical Immunology 2Non-Invasive Diagnostic Tests for Celiac Disease 2Non-Invasive Diagnostic Tests for Celiac Disease 3
(Date:7/14/2014)... New York, NY (PRWEB) July 14, 2014 ... authority Danny Seo and Harris Publications, debuts with a ... The lifestyle magazine looks at living the healthy, ... authoritative voice that covers everything from food, beauty, travel, ... America’s leading guru of green living. , “Instead of ...
(Date:7/14/2014)... According to the Blood Pressure Solution book ... that features a series of new information on high ... this book can help readers understand more about blood pressure. ... and effective methods to control hypertension naturally. ... Vkool, was penned by Ken Burge, a medical researcher and ...
(Date:7/14/2014)... July 14, 2014 Vaginal Mesh ... against seven different pelvic mesh manufacturers in the U.S. ... & Schulte LLC. The federal complaints are pending against ... 2327), American Medical Systems (MDL No. 2325), and C.R. ... there are 58,262 Vaginal Mesh lawsuit claims pending, according ...
(Date:7/14/2014)... TherapySites, the leading ... professionals, announced today its affiliation with the ... This new relationship allows TherapySites to continue ... members, adding exclusive benefits and promotional offers. , ... dedicated to providing online marketing solutions specifically for ...
(Date:7/14/2014)... July 14, 2014 Townsend Security, ... announced its new IBM i (AS/400, iSeries) Two ... (ISVs). As security threats evolve and make passwords ... struggle to modernize their applications and implement two ... makes it easy for ISVs on the IBM ...
Breaking Medicine News(10 mins):Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5Health News:TherapySites Partners With the Licensed Professional Counselors Association of North Carolina to Make Online Marketing Available to All Therapists 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 2Health News:IBM i ISVs Can Now Easily Integrate Mobile-Based Two Factor Authentication to Increase Security of Solutions 3
... another bout of West Nile, a potentially fatal, mosquito-spread infection. ... Control of the Harris county has said that the situation ... is still a large percentage of people in Houston who ... repellants or going out at night in short-sleeve shirts can ...
... out with the report that with UK leading the group, cancer ... use of new drugs. ,The study termed uptake of ... as well as in New Zealand, Poland, Czech Republic and South ... US were leaders in using new cancer drugs. ,The ...
... forty per cent (37 per cent) of British women and a ... unattractive on holiday as a result of excessive exposure to the ... has been conducted to highlight Sun Awareness Week, which kicks off ... over unsightly sunburn has meant that one in three Brits could ...
... eyes, say experts, who advise frequent short breaks every half ... ,Studies have shown that eyestrain and other vision problems ... people using video display terminals at work, said Kerry Beebe, ... ,The most common symptoms are eyestrain, blurred vision, ...
... the brakes on a racing heartbeat. ... the May 11 issue of Circulation Research how an enzyme ... of the heart's "fight-or-flight" reaction to adrenaline. ,A ... setting the pace of the beating heart, triggering its neighbor ...
... who is on a visit to the US, has ... in Hyderabad, promising to provide all necessary infrastructure. ... the signing of an MoU between Stanford University, the ... Research Institute) in California Thursday. ,Under the ...
Cached Medicine News:Health News:Health Authorities Fear West Nile Season Again in US 2Health News:Britains Complacent Attitude To Uptake Of New Cancer Drugs Revealed 2Health News:Burnt Brits Don't Feel Hot 2Health News:Many Hours on Computer may Harm Eyes 2Health News:Slowing the Racing Heart 2Health News:Reddy Asks Stanford University to Open Hyderabad Campus 2
... TFC Unite Device is the anterior alternative to ... Unite device features the same 70% fenestrations as ... fenestrations is paramount in the formation of new ... Unite system promotes load sharing between the device ...
Steinmann Pins are available in six point styles ranging from 5/64 to 3/16 in. diameters, in standard 9 in. (230 mm) lengths with threaded and smooth tips. Material: DePuy certified stainless steel. ...
... implant is the only approved radiolucent stand-alone ... assessment with the proven reliability of the ... Vista System is constructed of radiolucent, carbon-fiber ... unobstructed radiologic visualization, providing a new level ...
... Confirmatory (Western Blot): The Genetic Systems HIV-1 ... for the detection of antibodies to HIV-1. The ... of HIV-1 grown in the CEM cell line. ... devoid of HLA Class ll antigens, helps reduce ...
Medicine Products: